Tuesday, Viking Therapeutics Inc (NASDAQ:VKTX) released top-line results from its Phase 2 trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders such as obesity.
The Phase 2 VENTURE trial achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo.
Additionally, the study showed VK2735 treatment to be safe and well tolerated, with most treatment-emergent adverse events (TEAEs) being categorized as mild or moderate.
Patients receiving weekly doses of VK2735 demonstrated statistically significant reductions in mean body ...